StockNews.AI
POAI
StockNews.AI
84 days

Court Denies Renovaro Motion for an Expedited Trial in July

1. POAI disputes claims from Renovaro, asserting inaccuracies and lack of merit. 2. Delaware Court denied Renovaro's request for expedited trial due to delays. 3. POAI's trial is scheduled for November 12-13, 2025. 4. Company's AI platform predicts drug response with 92% accuracy. 5. POAI has over 150,000 tumor samples for drug discovery.

5m saved
Insight
Article

FAQ

Why Neutral?

While POAI's court dispute is significant, it doesn't reflect immediate revenue changes. Historical disputes often lead to temporary volatility without long-term detriment if properly managed.

How important is it?

The lawsuit's nature and POAI's commitment to defend indicate potential reputational and operational implications that could affect investor comfort and market trust.

Why Long Term?

The trial outcome could influence POAI's long-term operations and market position, similar to past legal disputes in biotech that shaped public perception.

Related Companies

RENBCGENEXAS
May 27, 2025 08:35 ET  | Source: Predictive Oncology Inc. PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro, Inc. Contrary to a press release issued by RENB, the Delaware Court of Chancery recently rejected RENB’s request for an expedited, two-day trial in July. The Court reached this decision citing RENB’s delay in bringing its action.  POAI fully intends to protect its rights and defend against the claims asserted by RENB that are premised on inaccurate allegations and lack any merit. The Court has scheduled trial for November 12-13, 2025. POAI looks forward to its day in Court. About Predictive Oncology Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA laboratory facility. Predictive Oncology is headquartered in Pittsburgh, PA. Investor Relations Contact: Mike MoyerLifeSci Advisors, LLC mmoyer@lifesciadvisors.com Forward-Looking Statements Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward- looking statements reflect Predictive Oncology’s current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about Predictive Oncology’s operations and the investments Predictive Oncology makes. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Predictive Oncology’s actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in Predictive Oncology’s filings with the SEC. Except as expressly required by law, Predictive Oncology disclaims any intent or obligation to update these forward-looking statements. Predictive Oncology does not give any assurance that Predictive Oncology will achieve its expectations described in this press release.

Related News